S&P Futures
3,746.75+2.50(+0.07%)Dow Futures
30,244.00+55.00(+0.18%)Nasdaq Futures
13,103.50-2.00(-0.02%)
China Medical System Holdings Limited (0867.HK)
Chart Events
Performance Outlook
| Previous Close | 12.260 |
| Open | 12.260 |
| Bid | 11.560 x 0 |
| Ask | 11.580 x 0 |
| Day's Range | 11.300 - 12.260 |
| 52 Week Range | 7.000 - 12.260 |
| Volume | 6,750,192 |
| Avg. Volume | 5,636,951 |
| Market Cap | 28.463B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 13.04 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.37 (3.26%) |
| Ex-Dividend Date | Aug 26, 2020 |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
CytoSorb Shipment Arrives in Designated Mainland China Hospitals to Treat Cytokine Storm in Critically-ill Patients with COVID-19 Coronavirus Infection
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader with more than 80,000 global treatments of its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients, announced today that its shipment of donated CytoSorb devices and accessories have arrived in Mainland China and have been delivered to designated hospitals to help treat "cytokine storm", shock, and acute respiratory distress syndrome in critically-ill patients stricken with the COVID-19 coronavirus.
- PR Newswire
CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader with more than 80,000 global treatments of its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients, and China Medical System Holdings Limited (CMS) (HKG:0867), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China and Asia, entered into an agreement to bring CytoSorb to mainland China to treat critically-ill patients with COVID-19 (fka Wuhan or 2019-nCoV) coronavirus infection.
